{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-085058","form_type":"8-K","ticker":"ATYR","cik":"0001339970","company_name":"aTYR PHARMA INC","filed_at":"2024-07-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.720968+00:00","generated_at":"2026-05-31T18:28:06.578627+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"aTyr Pharma completes Phase 3 enrollment for efzofitimod; topline data Q3 2025","bullets":["Enrolled 268 patients in EFZO-FIT study, exceeding target enrollment.","Trial conducted at 85 centers across 9 countries.","Topline data expected in Q3 2025.","Phase 3 study is pivotal, randomized, double-blind, placebo-controlled."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-085058","json":"https://secwatch.observer/filing/0000950170-24-085058.json","markdown":"https://secwatch.observer/filing/0000950170-24-085058.md","text":"https://secwatch.observer/filing/0000950170-24-085058.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024085058/0000950170-24-085058-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1339970/000095017024085058/atyr-20240722.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T18:28:06.578627+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}